Top Story Today
A Human Embryo Just Got a Typo Fix, and the Ethics Are About to Get Loud
Columbia University scientists pulled off the first-ever base edit of a human embryo, chemically swapping single DNA letters without cutting the double helix. The team targeted two genes: one linked to cholesterol (PCSK9) and another tied to sickle cell protection (fetal hemoglobin), even editing both simultaneously in some embryos. Unlike traditional CRISPR, which snips both DNA strands and hopes the cell patches things up, base editing produced no chromosomal abnormalities or large deletions. The embryos were never intended for pregnancy, and lead researcher Dieter Egli stressed this technology shouldn't be used to create a baby right now. But with each precision milestone, the uncomfortable question gets louder: when, if ever, should heritable genome edits be allowed?
Why it matters: Base editing is already in clinical trials for non-heritable therapies (Verve Therapeutics, Beam Therapeutics). Proving the same tools now work in the germline context collapses the gap between what's technically possible and what society has decided to allow, forcing regulators and ethicists into a conversation they've been deferring for years.
Read more →Clinical and Regulatory
The FDA Wants to Stream Your Clinical Trial Like Netflix
The FDA launched its first real-time clinical trial pilots with AstraZeneca and Amgen, streaming safety and endpoint data to regulators as studies run rather than in bulk at the end. AstraZeneca's Phase 2 lymphoma trial at MD Anderson has already transmitted validated signals. The initiative, part of Operation TrialBlazer, aims to cut U.S. trial timelines by 6 to 12 months and reverse the trend of early-stage research investment flowing overseas.
Read more →A Virus-Free CAR-T Just Cleared for Its First Human Test
German biotech T-CURX got Swissmedic approval to test TCX-001, the first non-viral CAR-T therapy, in up to 23 leukemia patients. Instead of expensive viral vectors, the therapy uses a "molecular copy-paste" transposon system that is significantly cheaper to manufacture. If it works, the approach could crack open the cost bottleneck that keeps CAR-T therapies north of $400,000 per treatment.
Read more →A $425K-per-Year Kidney Drug Gets the Green Light (Conditionally)
The FDA granted accelerated approval to Vera Therapeutics' TRUTAKNA for IgA nephropathy, a chronic kidney disease that disproportionately strikes young adults. The drug cut urine protein levels by 46% in its Phase 3 trial. But the approval hinges on a surrogate endpoint; kidney function data expected in Q3 2026 will determine whether TRUTAKNA earns full approval or becomes a cautionary tale.
Read more →Deals and Strategy
AstraZeneca Drops $2.1 Billion to Start a COPD War With Merck
AstraZeneca licensed a dual PDE3/PDE4 inhibitor from China's Sino Biopharmaceutical for up to $2.1 billion, aiming squarely at Merck's Ohtuvayre. Early Phase 2 lung function data slightly outperformed Ohtuvayre's, and AstraZeneca's massive respiratory salesforce gives it a distribution edge Merck lacks. The deal is also one of the clearest signals that China-originated respiratory assets now command multinational-scale economics.
Read more →Ipsen's $1.75 Billion Bet on Reactivating Cancer's Kill Switch
Ipsen is paying up to $1.75 billion for Kartos Therapeutics and its MDM2 inhibitor navtemadlin, which reactivates the body's p53 tumor suppressor in myelofibrosis patients. Only $450 million is upfront; the rest rides on a pivotal combination trial (POIESIS) expected to read out in 2027. If the data hit, Ipsen gets a potential blockbuster in a market with no approved disease-modifying therapies.
Read more →BioMarin's $270M Rare Disease Bet Just Hit a Wall
BioMarin's lead drug from its $270 million Inozyme acquisition raised the right biomarker but couldn't heal children's bones in a Phase 3 trial for ENPP1 deficiency. The enzyme replacement therapy nailed its biochemical target while missing the skeletal endpoint entirely, with no positive trends in secondary measures. A write-down of the acquired assets looks increasingly likely.
Read more →Big Picture
BMS Is Having a Banner Year. The Patent Cliff Doesn't Care.
Bristol Myers Squibb crushed Q2 estimates with $13 billion in revenue and hiked its full-year forecast by roughly $3 billion, fueled by a 22% Eliquis surge and a Growth Portfolio now generating 60% of total sales. The catch: Eliquis generics are already entering Europe, and a projected 98.6% revenue decline for the drug by 2031 means BMS is running a race against the steepest patent cliff in pharma history.
Read more →Lilly's $449 Zepbound Vials Are a Pricing Chess Move, Not a Price Cut
Eli Lilly slashed Zepbound's cost to $449 per month for cash-pay patients willing to use a vial and syringe instead of the autoinjector pen. The list price stays untouched. It's a strategic move in a price war with Novo Nordisk (Wegovy is at $349), a hedge against political pressure, and a way to build an affordability narrative for payer negotiations without actually cutting the number that matters to insurers.
Read more →Scientists Built a Cell From Scratch. It Eats, Grows, and Divides.
University of Minnesota researchers assembled SpudCell entirely from non-living, purified chemical components. It can feed on nutrients, copy its DNA, and split in two for about five to ten generations before breaking down. The creators are clear they haven't made life (it can't build its own ribosomes or sustain evolution), but the platform could become a programmable factory for therapeutic proteins that natural cells struggle to produce.
Read more →Pharma's $2 Trillion Forecast Comes With Fine Print
Evaluate projects global drug sales will double to $2 trillion by 2032, powered by GLP-1 obesity drugs and immunology therapies. But Wall Street has already trimmed obesity market estimates by 20 to 30% from peak hype levels, and Goldman Sachs expects average GLP-1 pricing to erode roughly 7% per year. The bull case depends on oral formulations expanding access; the bear case hinges on whether patients can afford to stay on treatment.
Read more →